Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 in ANCA-associated vasculitis
CTR20212971Phase 2Completed
- Sponsor
- 舒泰神（北京）生物制药股份有限公司；北京德丰瑞生物技术有限公司/ 舒泰神（北京）生物制药股份有限公司
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BDB-001 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by 舒泰神（北京）生物制药股份有限公司；北京德丰瑞生物技术有限公司/ 舒泰神（北京）生物制药股份有限公司. Started Feb 2022; status: completed.
02
Drugs
BDB-001
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on CTR20212971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212971.